Advertisement

Organisation › Details
Transgene S.A. (Euronext: TNG)
Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing cancer cells. The Company’s clinical-stage programs consist of a portfolio of therapeutic vaccines and oncolytic viruses: TG4050, the first individualized therapeutic vaccine based on the myvac® platform, TG4001 for the treatment of HPV-positive cancers, as well as TG6002, BT-001 and TG6050, three oncolytic viruses based on the Invir.IO® viral backbone. With Transgene’s myvac® platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The myvac® approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC. With its proprietary platform Invir.IO®, Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses. *
![]() |
Start | 1979-01-01 established |
Group | Mérieux (Group) | |
![]() |
Industry | therapeutic vaccine |
Industry 2 | immunotherapy | |
![]() |
Person | Riva, Alessandro (Transgene 202306– CEO before Chairman before Intima Bioscience + Ichnos Sciences + Gilead + Novartis) |
Person 2 | Bloom, Steven (Transgene 202202– US-based CBO before Boston Pharmaceuticals + Vavotar Life Sciences + Verastem Oncology) | |
![]() |
Region | Strasbourg |
Country | France | |
Street | 400 Boulevard Gonthier d’Andernach Parc d’Innovation d’Illkirch | |
City | 67405 Illkirch | |
Tel | +33-3-8827-9100 | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | D: 101 to 500 (2006-12-31) |
Currency | EUR | |
Annual sales | 28,019,000 (revenues, total (2007) 2007-12-31) | |
Profit | -5,521,000 (2007-12-31) | |
Cash | 84,100,000 (2014-09-30) | |
* Document for »About Section«: Transgene S.A.. (5/5/23). "Press Release: Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio". Strasbourg. | ||
Record changed: 2024-02-12 |
Advertisement

More documents for Mérieux (Group)
- [1] bioMérieux S.A.. (1/13/25). "Press Release: bioMérieux Strengthens Its Point of Care Presence with the Acquisition of the Immunoassay Start-up SpinChip". Marcy l’Étoile....
- [2] bioMérieux S.A.. (1/13/25). "Press Release: bioMérieux to Present at the 43rd Annual J.P. Morgan HealthCare Conference". Marcy l’Étoile....
- [3] Mérieux NutriSciences Corporation. (10/7/24). "Press Release: Mérieux NutriSciences Enters Agreement to Acquire Worldwide Food Testing Business of Bureau Veritas". Chicago, IL....
- [4] Deepull Diagnostics S.L.. (5/22/24). "Press Release: Deepull Appoints Didier Deltort to Its Board of Directors". Barcelona....
- [5] Transgene S.A.. (1/22/24). "Press Release: Transgene Further Strengthens Management Team with Appointment of James Wentworth as Chief Business Officer". Strasbourg....
- [6] bioMérieux S.A.. (10/19/23). "Press Release: bioMérieux Makes Strategic Investment in Oxford Nanopore". Oxford & Marcy-l’Etoile....
- [7] Oxford Biomedica plc. (9/20/23). "Press Release: Oxford Biomedica and Institut Mérieux Enter into Exclusive Negotiations with Respect to the Proposed Acquisition by Oxford Biomedica of ABL Europe". Oxford....
- [8] Transgene S.A.. (5/5/23). "Press Release: Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio". Strasbourg....
- [9] bioMérieux S.A.. (4/14/23). "Press Release: Oxford Nanopore and bioMérieux to Enter into a Strategic Partnership Agreement to Develop Innovative Infectious Disease Diagnostics". Oxford & Marcy-l’Etoile....
- [10] ABL Biomanufacutring. (3/27/23). "Press Release: ABL Appoints Stéphanie Colloud as General Manager and Chief Operating Officer to Lead European Activities". Lyon....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top